Organisation paid for research Program year 2025 Source: CMS Open Payments

Texas Neurology PA

Neither a doctor nor a teaching hospital

Research payments

$1,650,176

215 payments

Through program year 2025, Texas Neurology PA is reported as receiving $1,650,176 in research payments, across 215 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $286,550 47
2024 Research $281,460 44
2023 Research $314,380 37
2022 Research $185,013 30
2021 Research $113,217 26
2020 Research $184,790 16
2019 Research $284,766 15

Breakdown

Who paid Research payments · program years 2019–2025
  1. AbbVie, Inc. $438,840 89 payments
  2. Eli Lilly and Company $390,464 15 payments
  3. Genentech, Inc. $371,491 15 payments
  4. Mitsubishi Tanabe Pharma Development America, Inc. $125,403 8 payments
  5. Alexion Pharmaceuticals, Inc. $94,917 11 payments
  6. Allergan Inc. $86,492 30 payments
  7. H. Lundbeck A S $77,371 32 payments
  8. Otsuka Pharmaceutical Development & Commercialization, Inc. $37,917 4 payments
  9. Mitsubishi Tanabe Pharma America, Inc. $7,296 3 payments
  10. Amgen Inc. $6,561 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 2B Efficacy Safety Trial of Prasinezumab in Patients With Early Parkinson S Disease $351,671 14 payments
  2. Assessment of Safety, Tolerability and Efficacy of Ly3002813 Alone and in Combination With Ly3202626 in Early Symptomatic Alzheimers Disease $245,902 8 payments
  3. Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor $238,050 24 payments
  4. Effect of Ly3154207 on Cognition in Mild to Moderate Parkinsons Disease Dementia PDD - the Presence Study $131,619 4 payments
  5. Safety Study of Oral Edaravone Administered in Subjects With ALS $101,715 5 payments
  6. A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications $71,121 30 payments
  7. Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine $59,453 16 payments
  8. Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine $43,742 17 payments
  9. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine $40,998 11 payments
  10. Long Term, Observational, Registry of Patients With Generalized Myasthenia Gravis Who Have Received Treatment With Complement C5 Inhibition Therapies $34,370 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record